CN Patent

CN118159274A — 糖浆剂

Assigned to Chugai Pharmaceutical Co Ltd · Expires 2024-06-07 · 2y expired

What this patent protects

本发明涉及含有阿来替尼或其盐的糖浆剂，提供包含作为难溶性药剂的阿来替尼或其盐的具有经改善的流动性和/或服用性的糖浆剂。另外，本发明的糖浆剂相对于含有等量的阿来替尼或其盐的胶囊剂具有同等以上的血药浓度曲线、或生物学上等效、或者与含有等量的阿来替尼或其盐的胶囊剂相比具有增强的口服生物利用度。

USPTO Abstract

本发明涉及含有阿来替尼或其盐的糖浆剂，提供包含作为难溶性药剂的阿来替尼或其盐的具有经改善的流动性和/或服用性的糖浆剂。另外，本发明的糖浆剂相对于含有等量的阿来替尼或其盐的胶囊剂具有同等以上的血药浓度曲线、或生物学上等效、或者与含有等量的阿来替尼或其盐的胶囊剂相比具有增强的口服生物利用度。

Drugs covered by this patent

lenvatinib-mesylate (LENVATINIB MESYLATE)

Patent Metadata

Patent number: CN118159274A
Jurisdiction: CN
Classification: —
Expires: 2024-06-07
Drug substance claim: No
Drug product claim: No
Assignee: Chugai Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.